Metabolomics of patients with CAD and CKD

The morbidity and mortality of global Coronary artery disease (CAD) and chronic kidney disease (CKD) have continued to rise. Recent studies highlight that gut microbiome and their metabolites contribute to heart-kidney cross-talk.To better understand the enrichment and functional changes associated with microbiome-derived metabolites.We enrolled patients with CAD and CKD and untargeted metabolomics analysis was conducted on patient serum samples.We revealed many distinct metabolites and underscored significant differences in metabolites between the two groups.Thus, our data provides novel insights into regulation of metabolic function in patients with CAD and CKD and informs current efforts to bring metabolites predictive factors into clinical application.

全球范围内，冠状动脉疾病（Coronary artery disease, CAD）与慢性肾脏病（chronic kidney disease, CKD）的发病率与死亡率持续攀升。近期研究表明，肠道菌群（gut microbiome）及其代谢产物参与心肾串扰过程。为深入探究菌群源性代谢产物的富集特征与功能变化，本研究纳入冠状动脉疾病与慢性肾脏病患者，并对其血清样本开展非靶向代谢组学（untargeted metabolomics）分析。本研究鉴定出多种差异代谢产物，并证实两组患者的代谢产物谱存在显著差异。综上，本研究数据为冠状动脉疾病与慢性肾脏病患者的代谢功能调控提供了全新见解，同时为当前将代谢产物预测因子转化应用于临床实践的工作提供了重要参考依据。